We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Biopure Escapes Damages In SEC Suit, GC Doesn’t

Law360 (September 13, 2006, 12:00 AM EDT) -- Biopure Corp. won’t have to pay a cent to the Securities and Exchange Commission to settle allegations of issuing false and misleading public statements, though its general counsel wasn’t as lucky.

Under the settlement agreement, the company agreed to an injunction against future violations of federal securities laws for the statements it made in an effort to obtain Food and Drug Administration approval for its synthetic blood product Hemopure, the SEC said on Tuesday.

Biopure also agreed to retain an independent consultant to review the company’s...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.